Abstract: Retroviral which are resistant to inactivation by human serum. The retroviral vectors are produced in a cell line which is resistant to lysis by human serum, such cell lines including the HOS, Mv-1-Lu, HT1080, TE671, and human 293 cell lines, as well as cell lines derived therefrom. Such retroviral vectors are especially useful as in vivo gene delivery vehicles.
Type:
Grant
Filed:
August 17, 1995
Date of Patent:
September 14, 1999
Assignees:
Genetic Therapy, Inc., Institute of Cancer Research Royal Cancer Hospital
Inventors:
Michael Pensiero, Mary K. L. Collins, Francois-Loic Cosset, Yasuhiro Takeuchi, Robin A. Weiss
© 2024 Justia
